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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Prostaglandin E2 plays an important role in the maintenance of
gastric mucosal integrity. The level of biologically active prosta 
glandin E2 in the tissue is regulated by the balanced expression of
its synthetic enzymes, such as cyclooxygenase, and its catabolic
enzyme, 15 hydroxyprostaglandin dehydrogenase. We examined
the effect of rebamipide, a mucoprotective drug, on prostaglandin
E2 production and metabolism in the gastric tissue and its effect
on indomethacin induced gastric mucosal injury in mice. Rebamipide
suppressed indomethacin induced gastric mucosal injury. Suppres 
sive effect of rebamipide on indomethacin induced gastric mucosal
injury was also observed in cyclooxygenase 2 knockout mice. The
mice that were treated with rebamipide showed a 2 fold increase
in cyclooxygenase 2 mRNA expression in the gastric tissue, whereas
15 hydroxyprostaglandin dehydrogenase mRNA expression mark 
edly decreased as compared to vehicle treated control mice.
Rebamipide did not affect the expression of cyclooxygenase 1 in
the gastric tissue. Rebamipide did not increase prostaglandin E2
production in the gastric tissue; however, it induced a 1.4 fold
increase in the concentration of prostaglandin E2 in the gastric
tissue as compared to vehicle treated control mice. These results
suggest that the suppressive effect of rebamipide on non steroidal
anti inflammatory drugs induced gastric mucosal injury can be
attributed to reduced 15 hydroxyprostaglandin dehydrogenase
expression, which increases the prostaglandin E2 concentration in
the gastric tissue.
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Introduction Prostaglandin (PG) is a bioactive eicosanoid synthesized from
arachidonic acid liberated from membrane phospholipids. PG
plays important roles in multiple physiological processes, including
renal function, vascular homeostasis, bone remodeling, gastro-
intestinal function, pregnancy, and acute inflammatory responses.
PGs, especially PGE2, play an important role in maintenance of
gastric mucosal integrity via several mechanisms, including
regulation of gastric mucosal blood flow, kinetics of epithelial
cells, mucus synthesis, and inhibition of gastric acid secretion.(1)
Previous studies of the involvement of PGE2 in gastric mucosal
defense have focused on cyclooxygenase (COX), a rate-limiting
enzyme for synthesis of PGs. However, the total amount of
biologically active PGE2 in gastric tissue is regulated by the
balance between PGE2 synthesis and degradation; 15-hydroxy-
prostaglandin dehydrogenase (15-PGDH), which catalyzes the
oxidation of the 15(S)-hydroxyl group of prostaglandins, resulting
in the production of 15-keto-prostaglandins, greatly reduces the
biological activity of PGE2.(2)
Rebamipide (2-(4-chlorobenzoylamino-3-[2(1H)-quinolinon-4-
yl] propionic acid)), a mucosal protective agent, has been used
clinically for treating gastritis and peptic ulcers.(3,4) Clinical and
experimental data demonstrate that rebamipide accelerates gastric
ulcer healing,(5,6) prevents ulcer relapse,(6) and protects gastric
mucosa against acute injury caused by various noxious agents.(4,7–10)
It is reported that rebamipide actions are mediated by the stimula-
tion of prostaglandin synthesis,(11) inhibition of neutrophil activa-
tion,(12,13) and inhibition of generation of, and/or scavenging reac-
tive oxygen species.(14,15) However, the precise mechanism by
which rebamipide modulates PGE2 synthesis and metabolism in
gastric tissue remains unknown.
In this study, we studied the effect of rebamipide on (1)
indomethacin-induced gastric mucosal injury, (2) expression of
COX and 15-PGDH in gastric tissue, and (3) PGE2 levels in the
gastric tissue.
Materials and Methods
Animals. Seven-week-old C57BL/6 mice were purchased
from Charles River Japan, Inc. (Yokohama, Japan). Seven to ten-
week-old COX-2-knockout mice (background: C57BL/6) and
wild-type littermates were purchased from the Jackson Laboratory
(Bar Harbor, ME). Animals were housed in polycarbonate cages
with paper chip bedding in an air-conditioned, biohazard room
with a 12-h light-dark cycle. All animals had free access to food
and water. All experimental procedures were approved by the
Animal Care Committee of the Osaka City University Graduate
School of Medicine.
Experimental protocol. Sixteen hours after fasting, re-
bamipide (30 or 100 mg/kg body weight (BW), supplied by
Otsuka Pharmaceutical Co., Tokyo, Japan) or vehicle (0.25%
carboxymethylcellulose) was given orally to mice. Four hours
after administration of rebamipide or vehicle, indomethacin
(30 mg/kg BW, Sigma Chemical Company, St. Louis, MO) was




administration of indomethacin. Gastric mucosal injury was
evaluated by measuring the injured area in the gastric mucosa
defined as areas with clots of blood.
Assessing mRNA expression for COX 1, COX 2 and 15 
PGDH in the gastric tissue by real time quantitative reverse
transcription polymerase chain reaction (RT PCR). Mice were
orally treated with the vehicle or rebamipide (30 or 100 mg/kg
BW, respectively) and their stomachs were removed after 4 h.
Real-time quantitative RT-PCR analyses were performed as
previously described.(16,17) In brief, total RNA was isolated from
the gastric tissue using an ISOGEN kit (Nippon Gene, Tokyo,
Japan) according to the manufacturer’s protocol. PCR primers
and TaqMan probes for COX-1 and -2 were designed using the
software program, Primer Express (PE Applied Biosystems,
Foster City, CA). The primers and probes for measuring 15-PGDH
mRNA in the gastric tissue were chosen using the online Applied
Biosystems catalogue. TaqMan probes were labeled with a
reporter fluorescent dye (6-carboxyfluorescein) at the 5' end and
a fluorescent dye quencher (6-carboxytetramethylrhodamine) at
the 3' end. For the mouse COX-1, the sense primer was 5'-
CATCAAGGAGTCCCGAGAGAT-3', the antisense primer was
5'-TAAGGCTTCAAGCCAAACCTC-3', and the TaqMan probe
was 5'-CGCCTACAGCCCTTCAATGAATACCGA-3'. For mouse
COX-2, the sense primer was 5'-AAGCCCTCTACAGTGACA
TCGA-3', the antisense primer was 5'-ATGGTCTCCCCAAAGA
TAGCAT-3', and the TaqMan probe was 5'-CTGCTGGTGGAA
AAACCTCGTCCA-3'. Real-time quantitative RT-PCR analyses
were performed using the ABI PRISM 7700 Sequence Detection
System and software (PE Applied Biosystems). The reaction
mixture was prepared according to the manufacturer’s protocol
using the Platinum qRT-PCR ThermoScript One-Step System
(Invitrogen, Carlsbad, CA). Thermal cycling conditions were
50°C for 30 min and 95°C for 5 min, followed by 45 cycles of
amplification at 95°C for 15 s and 60°C for 1 min. Total RNA was
subjected to real-time quantitative RT-PCR for measurement of
target genes and GAPDH as an internal standard using TaqMan
GAPDH control reagents (PE Applied Biosystems). Expression of
mRNA in the gastric tissue was standardized to GAPDH mRNA,
and mRNA levels were expressed as ratios to the mean values of
GAPDH mRNA in the normal gastric tissue.
Measuring PGE2 synthesis in the gastric tissue. PGE2
production by the gastric tissue was assessed by using a vortex
method, developed from that originally described by Whittle
et al.(18) Mice were orally treated with the vehicle or rebamipide
(30 or 100 mg/kg BW, respectively), their stomachs were removed
after 4 h and placed in polypropylene tubes containing 1 ml of
Tris-HCl buffer (150 mM, pH 8.2) for 1 min, and then centrifuged
at 9,000 rpm for 40 s. Supernatant was discarded and 1.5 ml of
fresh Tris-HCl buffer was added. Tubes were then simultaneously
mixed in a vortex for 1 min, and 30 µl of 10 mM indomethacin
(Sigma Chemical) was added immediately to inhibit excessive
COX activity. Tubes were centrifuged at 9,000 rpm for 40 s.
Supernatants were collected and stored at −80°C. The amount of
PGE2 in the supernatant was determined by enzyme immunoassay
(PGE2 EIA kit, Cayman Chemical Co., Ann Arbor, MI). PGE2
production was expressed as nanogram of PGE2 per gram of tissue
per minute.
Measuring PGE2 levels in the gastric tissue. Mice were
orally treated with the vehicle or rebamipide (30 or 100 mg/kg
BW, respectively) and their stomachs were removed after 4 h.
The gastric tissue was isolated, weighed, and placed in a tube
containing 100% ethanol plus 0.1 M indomethacin. The samples
were then sheared with scissors, homogenized, and centrifuged
at 12,000 rpm for 10 min at 4°C. The supernatant of each sample
was used for determination of PGE2 using a PGE2 EIA kit
(Cayman Chemical Co.).
Statistical Analysis. Values are the mean ± SE. Kruskal-
Wallis  H test was used to test for significance of differences
among treatment-group means. Results were examined by Mann-
Whitney U test with Bonferroni correction. Differences with p
values less than 0.05 were considered significant.
Results
The effect of rebamipide on indomethacin induced gastric
mucosal injury. Indomethacin induced hemorrhagic lesions in
the stomach. Rebamipide suppressed formation of hemorrhagic
lesions induced by indomethacin in a dose-dependent manner
(Fig. 1a). Suppressive effect of rebamipide on indomethacin-
induced gastric mucosal injury was also observed in COX-2-
knockout mice (Fig. 1b).
The effect of rebamipide on COX 1, COX 2 and 15 PGDH
mRNA expression in the gastric tissue. The mice that were
treated with 100 mg/kg BW of rebamipide showed a 2-fold
increase in COX-2 mRNA expression in the gastric tissue,
while 15-PGDH mRNA expression decreased by 26% or 89%
in the mice treated with 30 mg/kg BW or 100 mg/kg BW of
rebamipide, respectively, compared with vehicle-treated control
Fig. 1. The effect of rebamipide on indomethacin induced gastric
mucosal injury in wild type or COX 2 knockout mice. (a) Mice were
given indomethacin s.c. in a dose of 30 mg/kg and killed 6 h later.
Rebamipide (30 or 100 mg/kg) was given p.o. 4 h before indomethacin.
(b) COX 2 knockout or wild type mice were given indomethacin s.c. and
killed 6 h later. Rebamipide at 100 mg/kg was given p.o. 4 h before
indomethacin. Data are presented as means ± SE for 4–6 mice. J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 151
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mice. Rebamipide did not affect COX-1 mRNA expression (Fig. 2).
Effect of rebamipide on PGE2 synthesis and levels in the
gastric tissue. Rebamipide did not increase PGE2 synthesis in
the gastric tissue (Fig. 3a); however, it induced a 1.4-fold increase
in PGE2 concentration in the gastric tissue compared with vehicle-
treated control mice (Fig. 3b).
Discussion
Our present study demonstrated that rebamipide suppresses
indomethacin-induced gastric mucosal injury. Notably, even in
COX-2-knockout mice, rebamipide exerted preventive effects
against indomethacin-induced gastric mucosal injury. Rebamipide
up-regulated PGE2 levels accompanied by marked down-
regulation of 15-PGDH in the gastric tissue, suggesting that
rebamipide suppresses indomethacin-induced gastric mucosal
injury via down-regulation of 15-PGDH.
Indomethacin induces gastric mucosal injury by reducing PG
levels via inhibition of cyclooxygenase activity. It is reported
that prior administration of 16,16-dimethyl PGE2, which is not
catabolized by 15-PGDH, prevents injury development in the
stomach.(19,20) These results suggest that rescuing physiologically
active PGE2 by reducing the activity of its catabolic enzyme, 15-
PGDH, could suppress indomethacin-induced gastric mucosal
injury. Accumulating evidence suggest that reduction of 15-PGDH
levels enhances the physiological effects of PGE2. Recent studies
have shown that reduction of 15-PGDH levels occurs in associa-
tion with an aggressive phenotype and unfavorable prognoses in
breast,(21) prostate,(22) lung,(23) colorectal,(24,25) and medullary thyroid
cancers.(26) Our recent study suggests that down-regulation of 15-
PGDH induces cell proliferation in gastric cancers accompanied
by up-regulation of PGE2 level.(27) 15-PGDH in the bladder cancer
cell-lines increases motility and anchorage-independent growth.(28)
From these findings, it is possible that rebamipide may prevent
indomethacin-induced gastric mucosal injury via suppressing
PGE2 catabolism by reducing 15-PGDH expression.
The mechanisms whereby rebamipide reduces 15-PGDH
expression in the gastric tissue remain unknown. Activation of
epidermal growth factor-receptor (EGFR) signaling pathway has
been proposed as a possible mechanism whereby 15-PGDH
expression may be reduced.(29) A recent study suggests that
rebamipide activates EGFR and mitogen-activated protein kinase
(MAPK) in conjunctival goblet cells.(30) From these findings, we
speculate that rebamipide may down-regulate 15-PGDH expres-
sion via activation of EGFR and MAPK in gastric epithelial cells.
Previous reports demonstrate that rebamipide induces COX-2
expression, increases PGE2 levels, and enhances gastric mucosal
defense in a COX-2-dependent manner in rat gastric mucosa(31)
and rat gastric epithelial cells.(32) In addition of induction of COX-
2, it is also possible that reduction of 15-PGDH by rebamipide
may also contribute to increase PGE2 levels in the gastric tissue.
We demonstrate that rebamipide promotes healing of gastric
Fig. 2. The effect of rebamipide on COX 1, COX 2 and 15 PGDH mRNA expression in the gastric tissue. Mice were given rebamipide (30 or 100 mg/kg)
p.o. and killed 4 h later. Data are presented as mean ± SE for 4–6 mice.doi: 10.3164/jcbn.10 75
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ulcers through both COX-2-dependent and COX-2-independent
mechanisms.(12) On the contrary, Kleine A. et al.(11) concluded that
the increase in prostaglandin formation results from stimulation of
biosynthesis and not inhibition of degradation because release of
15-keto-PGE2, a metabolites of PGE2, in gastric mucosal tissue of
rats was not impaired by rebamipide. This discrepancy might be
due to differences among the studies in the animal model,the study
design, the period of treatment with rebamipide and the methods
of assessment used.
In conclusion, rebamipide inhibits indomethacin-induced gastric
mucosal injury. Rescuing physiologically active PGE2 by reducing
15-PGDH expression may be a potential mechanism for this effect.
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